Tobias Sing

List of Publications by Year
in descending order

17 papers	3,614 citations	706676 14 h-index	993246 17 g-index
17 all docs	17 docs citations	17 times ranked	8375 citing authors

#	Article	IF	Citations
1	Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV‑1 Non‑nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. ChemMedChem, 2011, 6, 2203-2213.	1.6	14
2	Dynamics of NRTI Resistance Mutations during Therapy Interruption. AIDS Research and Human Retroviruses, 2009, 25, 57-64.	0.5	11
3	Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype. Antiviral Therapy, 2009, 14, 273-283.	0.6	10
4	Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model. Journal of Clinical Microbiology, 2007, 45, 279-284.	1.8	90
5	Structural Descriptors of gp120 V3 Loop for the Prediction of HIV-1 Coreceptor Usage. PLoS Computational Biology, 2007, 3, e58.	1.5	76
6	Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. Journal of Virology, 2007, 81, 11507-11519.	1.5	62
7	Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. Aids, 2007, 21, F17-F24.	1.0	127
8	Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates. Antiviral Therapy, 2007, 12, 1097-1106.	0.6	137
9	Improved Prediction of Response to Antiretroviral Combination Therapy using the Genetic Barrier to Drug Resistance. Antiviral Therapy, 2007, 12, 169-178.	0.6	42
10	Bioinformatics-assisted anti-HIV therapy. Nature Reviews Microbiology, 2006, 4, 790-797.	13.6	82
11	Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. Journal of Virology, 2006, 80, 7186-7198.	1.5	64
12	Arevir: A Secure Platform for Designing Personalized Antiretroviral Therapies Against HIV. Lecture Notes in Computer Science, 2006, , 185-194.	1.0	11
13	Compensatory Mutations at the HIV Cleavage Sites P7/P1 and P1/P6-Gag in Therapy-Naive and Therapy-Experienced Patients. Antiviral Therapy, 2006, 11, 879-888.	0.6	58
14	HIV-1 gp120 V3 Loop for Structure-Based Drug Design. Current Protein and Peptide Science, 2005, 6, 413-422.	0.7	59
15	Estimating HIV Evolutionary Pathways and the Genetic Barrier to Drug Resistance. Journal of Infectious Diseases, 2005, 191, 1953-1960.	1.9	76
16	ROCR: visualizing classifier performance in R. Bioinformatics, 2005, 21, 3940-3941.	1.8	2,677
17	Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking. Lecture Notes in Computer Science, 2005, , 285-296.	1.0	18